StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) income statement

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30508% above fair value
$33.27+0.77 (+2.37%)

Close on Nov 18, 2026Market cap $155.75MP/E –Yield –

Korsana Biosciences, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-359.2%
Net margin
-353.0%
Return on equity, FY2025
-39.3%

Financial strength

Current ratio
0.82
Debt to equity
–
Debt to assets
–
Cash to current liabilities
75.5%

Valuation

P/E ratio
–
Price to sales
81.97
Price to book
30.62
Dividend yield
–

See a number that looks wrong?